VCN Biosciences

VCN Biosciences SL is a private company focused on developing new treatments for tumors that lack effective therapies. The company utilizes an oncolytic adenovirus technology platform to design highly selective and efficient formulations that replicate and self-amplify exclusively in tumor cells. VCN Biosciences' mission is centered on developing novel cancer therapeutics based on highly selective oncolytic adenoviruses with the potential for tumor treatment. The company conducts comprehensive development of new viral candidates, starting from design through preclinical studies and first-in-human efficacy trials (Phase I and II clinical trials).